Last reviewed 2026-04-23 · How we verify

Reduced dose intensity of IO

Reduced dose intensity of immunotherapy (IO) aims to maintain anti-tumor efficacy while decreasing treatment-related toxicity through lower or less frequent dosing schedules.

Reduced dose intensity of immunotherapy (IO) aims to maintain anti-tumor efficacy while decreasing treatment-related toxicity through lower or less frequent dosing schedules. Used for Cancer treatment optimization via dose-reduced immunotherapy regimens (specific tumor types under investigation in UNICANCER phase 3 trial).

At a glance

Mechanism of action

This is a dosing strategy rather than a novel drug, where standard immunotherapy agents (such as checkpoint inhibitors) are administered at lower doses or extended intervals. The approach seeks to optimize the benefit-risk profile by reducing cumulative exposure to immune-activating agents, thereby lowering the incidence and severity of immune-related adverse events while preserving therapeutic activity.

Approved indications

• Cancer treatment optimization via dose-reduced immunotherapy regimens (specific tumor types under investigation in UNICANCER phase 3 trial)

Common side effects

• Immune-related adverse events (reduced incidence expected vs. standard dosing)
• Fatigue
• Rash
• Diarrhea

Key clinical trials

• Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Reduced dose intensity of IO CI brief — competitive landscape report
• Reduced dose intensity of IO updates RSS · CI watch RSS
• UNICANCER portfolio CI